Moreover, depletion of MTHFD2 impairs aggressivephenotypes and causes cell death in multiple cancers, including breastcancer, colorectal cancer, central nervous system tumors, lung cancer,ovarian cancer, renal cancer, melanoma, and leukemia.6−8 These results suggested that targeting MTHFD2 is a promising strategyfor cancer therapy.9,10. This evidence concerns the gene MTHFD2 and renal carcinoma.